Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Abstract

35Background: To explore the cellular immunity and cytokines status of NCP patients and to predict 36 the correlation between the cellular immunity levels, cytokines and the severity of patients. 37Methods: 123 NCP patients were divided into mild and severe groups. Peripheral blood was 38 collected, lymphocyte subsets and cytokines were detected. Correlation analysis was performed on 39 the lymphocyte subsets and cytokines, and the differences between the indexes of the two groups 40 were analyzed. 41Results: 102 mild and 21 severe patients were included. Lymphocyte subsets were reduced in two 42 groups. The proportion of CD8 + T reduction in the mild and severe group was 28.43% and 61.9%, 43 respectively; The proportion of B cell reduction was 25.49% and 28.57%; The proportion of NK 44 cell reduction was 34.31% and 47.62%; The detection value of IL-6 was 0 in 55.88% of the mild 45 group, mild group has a significantly lower proportion of patients with IL-6 higher than normal than 46 severe group; There was no significant linear correlation between the lymphocyte subsets and 47 cytokines, while significant differences were noticed between the two groups in CD4 + T, CD8 + T, 48 IL-6 and IL-10. 49Conclusions: Low levels of CD4+T and CD8+T are common in severe NCP. IL-6 and IL-10 levels 50were higher in severe patients. T cell subsets and cytokines can be used as one of the basis for 51 predicting the transition from mild to severe. Large number of samples are still needed to confirm 52 the "warning value" of CD4 + T, CD8 + T IL-6 and IL-10. 53

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

“…Chaolin Huang et al confirmed the occurrence of the J o u r n a l P r e -p r o o f cytokine storm in the COVID-19 patients in ICU rather than those in non-ICU patients [7]. Based on the excessive cytokines responses, Suxin Wan et al claimed that IL-6 and IL-10 levels could be used as one of the bases for predicting the outcome and prognosis of the COVID-2019 [20]. In this study, host cells infected with HCoV-229E and SARS-COV-2 increased the cytokine release such as TNF-α, IL-6, CCL-2/MCP-1, and CXCL-10/IP-10, which was suppressed by LH in a dose-dependent manner.…”

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

“…Cytokine release syndrome is a vital factor that aggravates disease progression. A higher levels of IL-6 and IL-10, and lower levels of CD4+T and CD8+T are observed in COVID-19 patients parallel with the severity of the disease [40].…”

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

“…One study analyzed the lymphocyte subsets and cytokines in 123 patients, all patients had ly mphcytopenia, The percentage of CD8 + T cell reduction were 28.43% and 61.9% in mild and severe group respectively, and the NK cell reduction were 34.31% and 47.62% respectively ，in mild and severe groups. Also, serum IL-6 levels in severe group were significantly higher than that in mild group [9]. In addition, the expression of HLA-DR in CD4 + and CD8 + cells was increased, CD4 + CCR4 + CCR6 + Th17 cells also increased, and the cytotoxic particles such as perforin and granolysin were highly expressed in CD8 + T cells [10].…”